Pharmaceutical company Medicines Co. said Monday a European advisory committee gave the company's Angiox a positive recommendation for expanded use in adults with acute coronary syndromes.
The drug, called Angiomax in the U.S., is already approved for patients undergoing percutaneous coronary intervention, commonly referred to as angioplasty.
The positive recommendation was issued by the Committee for Medicinal Products for Human Use of the European Medicines Agency. The European Commission will take the opinion into account when reviewing the drug application.
The company is seeking similar additional approval for the drug from the Food and Drug Administration.